Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma

• Príomhchruthaitheoirí: Panarat Orachum (Údar), Amornrat Temtanakitpaisan (Údar), Pilaiwan Kleebkaow (Údar), Bandit Chumworathayi (Údar), Sanguanchoke Luanratanakorn (Údar), Apiwat Aue-angkul (Údar), Yuwadee Itarat (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Korean Society of Obstetrics and Gynecology, 2022-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.
• Notes: 2287-8572; 2287-8580; 10.5468/ogs.22102
• Keywords: high-grade serous ovarian carcinoma; immunohistochemistry p53; ovarian cancer; survival outcome; progression-free survival; Gynecology and obstetrics; RG1-991
• Source: Obstetrics & Gynecology Science, Vol 65, Iss 5, Pp 459-467 (2022)

Objective To investigate the prevalence of p53 mutations and associated factors between immunohistochemistry (IHC) and p53 staining patterns among patients with high-grade serous ovarian carcinoma (HGSOC). Methods This study is a retrospective review. A total of 62 patients with HGSOC underwent surgery at Srinagarind Hospital between January 2016 and December 2020. Histological examination was performed based on a combination of morphology and IHC staining with p53. The p53 immunostaining pattern was interpreted as a missense mutation, nonsense mutation, or a wild-type pattern. Missense (p53 overexpression pattern) and nonsense (null expression p53 pattern) mutations were considered p53 mutations. A wild-type pattern was defined as a p53 non-mutation. Results p53 mutations were identified in 93.6% of the patients. Subgroup analysis of the p53 mutation group between the p53 overexpression pattern and the p53 null expression pattern in terms of clinicopathological characteristics and initial treatment was performed. Patients with the p53 overexpression pattern had significantly more omental metastases than those with the p53 null expression pattern (87.8% vs. 64.7%, P=0.042). There were no statistically significant differences in median progression-free survival (PFS) (9 vs. 10 months, P=0.813) or median overall survival (OS) (12 vs. 17 months, P=0.526) between the two groups. Conclusion The prevalence of p53 mutations in HGSOC patients in this study was 93.6%. Omental metastasis is a significant pathological factor in predicting overexpression p53 pattern in HGSC. However, IHC analysis of the p53 staining pattern did not affect OS or PFS among patients with HGSOC.